Pharma Partnering & Investment World Asia 2012 - list of speakers

Dr. Sam Azoulay is the Senior Vice President, Medical & Development, of the Emerging Markets and Established Products Business Units for Pfizer Inc. Dr. Azoulay joined Pfizer as a result of the company’s acquisition of Parke Davis, Warner Lambert in 2000, where he had served as Development Site Head in Eastleigh, UK and Head of Cardiovascular...

Mark Bach was trained as a pediatrician at Baylor College of Medicine and as a Pediatric Endocrinologist at the National Institutes of Health. He joined the pharma industry in 1993. Mark spent 16 years at Merck & Co., including 7 years clinical science, 3 years in Tokyo as deputy head of clinical development, and 5 years running Asia Pacific...

Mr. Bienaimé joined BioMarin in May 2005 as Chief Executive Officer and member of the Board of Directors, bringing with him over 25 years of experience in the biotechnology and pharmaceutical industries. Under his leadership, the market capitalization of BioMarin went from around $450 million in May 2005 to over $3.5 billion in Nov 2011. BioMarin...

Nettie Buitelaar is managing director of Leiden Bio Science Park in the Netherlands. After obtaining her Ph.D. in bioprocess engineering she worked in biotechnology research management for some ten years. After obtaining her MBA she transferred to the VC industry, after which she was the national director of the Dutch ‘BioPartner’ program, aimed...

Andreas has been a memmber of the Bayer HealthCare Executive COmmittee as Head of Pharmaceuticals Reserch since February 2007. He has also been in charge of Research in the Animal Health Division since March 2011. Andreas has worked at various research institutes in Germany and USA prior to joining the industry. His scientific work has been...

Mr. Casey is responsible for Quintiles’ corporate development and partnering functions for the Asia, Australia and Africa regions. These responsibilities include deal structuring, negotiation and due diligence. Mr. Casey has been with Quintiles for 17 years. He has held leadership positions within Marketing and headed the CEO’s office within...

Vivek joined Kibow Biotech in 2012 as an advisor for strategic partnerships and to lead global marketing initiatives. In 2011, he did healthcare marketing/strategy consulting in three countries (US, Belgium, and India) to gain hands-on global healthcare marketing perspective beyond the US market. Prior to becoming a healthcare marketing...

Emma leads the mainland China corporate practice of Clifford Chance and the healthcare and life sciences group in Asia. She is bilingual in Mandarin and English and has spent over 15 years in Asia advising businesses on their investments in China. In addition to advising on various cross-border acquisitions and divestments for pharmaceutical and...

John has a vast amount of experience in investing in lifesciene companies and is also special advisor to the Singapore Economic Development Board. He also serves as Board Chairman of Ambrx and Envoy Therapeutics as well as on the Boards of Directors of Igenica, Ingenuity Systems, Marcadia, PhaseRx and Wildcat Discovery. He will be addressing...

Mr. Dunlop has over twenty years of experience successfully partnering new life science technologies to deliver competitive returns to international investors. Mr. Dunlop previously led MASA Life Science Ventures, LP ("MLSV" – www.mlsvfund.com). MLSV's investors include ‘top ten’ Japanese & Korean Pharmaceutical companies, the largest distributor...

Anders is responsible for R&D operating across drug development and life cycle management delivering submissions and approvals in Astrazeneca. He was also in charge of strategy, portfolio and alliances in the company. He will be discussing in our keynote panel on the views of Asia as a source of growth and innovation for pharmas to narrow the gap...

Carrie has led the Life Sciences practice in CM Capital Investments for over 10 years, investing and been the inventor of a number of patents and has been involved in the complete product lifecycle, including medical research in London and developing, licensing and marketing new products in Australia. She will take you through the steps on...

Ling is a partner in Clifford Chance's Hong Kong office, where she heads the Intellectual Property Group in Asia and acts as Co-Head of Clifford Chance’s Litigation and Dispute Resolution Practice in China. Ling is admitted in both Hong Kong and England & Wales. A key focus of Ling’s practice is contentious and non-contentious intellectual...

Professor Hodnett is Dean of the faculty of science and engineering at the University of Limerick having previously served as Head of Department of Chemical and Environmental Sciences (1995-1998) and Director of the Materials and Surface Science Institute (1999-2003). He is currently the lead PI on the SFI sponsored Solid State Pharmaceutical...

Hong Bo has been instrumental in several life science start-up operations in Asia. In this conference, she will bring you through the steps how emerging companies from Asian Biotech hubs can effectively tap into available funding opportunities.

Dr. Wang Jian is the director of BGI. After graduation he conducted postdoctoral research in USA from 1988-1990 and worked as a senior research fellow at the University of Washington during 1990-1994. Here he acted as one of the main team leaders of management and decision-making for research and application projects, leading the team to establish ...

With 25 years of diverse industry background in biotechnology including 10 years of executive management experience, Nazlee brings in strong acumen in both the technical and business aspects of biotechnology to BiotechCorp. Recognised for his wide industrial leadership, Nazlee played a pivotal role in the formulation of Malaysia’s National...

Dr Phil Kearney joined Merck Sharp & Dohme Australia in 2007 as the key scout for innovative research and development in Australia, New Zealand and some parts of South East Asia. The Sydney-born scientist has the challenge of uncovering and commercialising discoveries by local researchers that have strong potential to benefit the health of people...

Monika Lessl is head of Alliance Management at Global Innovation Sourcing at Bayer HealthCare in Berlin, Germany. She is responsible for the set up and management of strategic alliances with academic and biotech partners, the development of collaboration strategies as well as the establishment of novel and innovative partnership models and open...

Mr Damien Lim is co-founder and General Partner of BioVeda Capital. He has more than 21 years’ experience in private equity and investment banking. He was previously Director, Investments with Prime Partners, a boutique fund in Singapore. Prior to Prime Partners, Mr Lim was Executive Director of Vickers Ballas Asset Management where he was...

Mr Wheaton Little is currently the Director, Operations and Strategy, World Wide Business Development, Asia of GSK where he coordinates and sources business development opportunities for GSK R&D from Asia Pacific for all therapeutic areas. Mr Little also manage the Academic Centre of Excellence in Singapore, which focuses on transitioning early...

Mr. Andy A. Liu is currently the President of Asia Pacific and China for IMS Health. He is responsible for IMS Health operations in over 15 countries in Asia Pacific. Previously Mr. Liu served as Vice President of Strategy and Business Development for IMS Health leading deal transactions, acquisitions, joint ventures and partnerships for Asia...

Deanna Petersen joined Shire in 2009 as Vice President of Business Development for Shire Human Genetic Therapies (HGT). Deanna is a broadly skilled senior executive with 15 years of leadership experience in strategic planning and global business development. Deanna is a member of Shire HGT’s senior leadership team and is responsible for...

Hui Hsing Ma is TVM Capital’s General Partner responsible for the East Asia region. She has over ten years experience in the life sciences industry, starting in 2000 as Senior Vice President, at the global VC firm, Vertex Management, where she co-led their US$80 million investments in US and European Biotech companies and funds. Since 2003, she...

Ian Marison joined NIBRT (National Institute for Bioprocess Research & Training) as Interim Director in January 2011 from Dublin City University. NIBRT is a world-class institute that provides training, educational and research solutions for the Irish and international bioprocessing industry in state of the art facilities. Located in South...

Kiran Mazumdar-Shaw's pioneering efforts in biotechnology have drawn global recognition both for Indian Industry and Biocon. Her unique vision has steered Biocon's transition from an industrial enzymes company to an integrated biopharmaceutical company with strategic research initiatives. Biocon is today recognised as India's pioneering biotech...

Dr. Erich Mohr, a Professor of Medicine and Psychology at the University of Ottawa until 1997 has over 25 years of experience in experimental therapeutics of CNS disorders. Dr. Mohr received his Ph.D. in Neuropsychology from the University of Victoria in 1982. He became a Fogarty Fellow at the National Institutes of Health in 1983 and completed...

Currently Mr. Rindell is Senior Director of Corporate Development for Amylin Pharmaceuticals, Inc., a position he has held since 2005. He has led and participated in a number of key global transactions in both diabetes and obesity, including transactions with Shionogi Pharmaceuticals, BIOCON Ltd., Takeda Pharmaceuticals and selected device...

Alfred Scheidegger is the founder and CEO of Nextech Venture, Ltd., a globally active investment management firm based in Zurich, Switzerland. Nextech Venture manages and advises three investment funds of USD 166 million with a focus on oncology. Prior to founding Nextech Venture Ltd., Mr. Scheidegger was managing director and member of the board...

Ravi studied in the UK obtaining B.Sc. in Pharmacology, Ph.D. and MBA. He spent several years in Research (London University, Zurich University Hospitals, Ciba Geigy Basel), Clinical Development (SmithKline Beecham) and Sales & Marketing (Novartis). In 1999 Ravi moved to Business Development & Licensing at Novartis, where he spent 8 years in...

Goro leads his team on identifying Life Science spin-out opportunities in Asia. He was also involved with investments in biotechnology and specialty pharmaceutical companies including Arrow Therapeutics, Cyclacel Pharmaceuticals and Plexxikon. Goro will address the criteria’s that VC’s look for when investing in early start up companies.

Dr. Anand Tharmaratnam is Senior Vice President and Head of Asia Markets, Clinical Development for Quintiles. In this role, Dr. Tharmaratnam has responsibility for the Quintiles clinical development business across the Asia-Pacific region, including Japan. In the Asia-Pacific region alone, Quintiles has more than 25 offices and employs...

Dr. Lujing Wang has extensive experience in the areas of health economics, pricing, and market access. He has assisted many leading pharmaceutical and biotech companies in developing pricing, reimbursement, market access, and evidence generation strategies in the US, the EU, and key emerging markets. He is also a thought leader in assessing...

Dr. Stella Xu is an Regional Head with Roche Partnering Asia. Her major responsibilities include searching potential licensing opportunities (products / technologies), and supporting transaction discussions & alliance management in Asia. Prior to her current position, Stella had held multiple global positions in Roche Partnering in the US and led...

Chihiro has more than 30 years of pharmaceutical industry experience and is a highly regarded individual of the industry. He has led the company’s global business expansion and managed several deals including the acquisition of OSI Pharmaceuticals and alliances with Ambit Biosciences and Medivation. Prior to his current position, Chihiro served as ...